GVHD

Patrick DalyASH Annual Meeting 2022 | August 28, 2023
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and ...
Read More
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
In a phase 2 trial, presented at the 64th ASH Annual Meeting and Exposition, researchers compared itacitinib monotherapy ...
Patrick DalyASH Annual Meeting 2022 | April 24, 2023
For years, the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic cell ...
DocWire News EditorsASCO 2022 | April 3, 2023
In a meta-analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers evaluated ...
DocWire News EditorsASCO 2022 | October 16, 2023
According to research presented at the 2022 American Society of Clinical Oncology Annual Meeting, graft-versus-host ...
DocWire News EditorsASCO 2022 | August 25, 2023
Hispanic patients had a significantly lower cumulative incidence of chronic graft-versus-host disease (GVHD) than ...
DocWire News EditorsASCO 2022 | October 16, 2023
The first-in-human, phase I clinical trial of ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T-cell ...
Patrick DalyASCO 2022 | August 28, 2023
The recently FDA-approved ruxolitnib should be utilized more in the treatment of chronic steroid-refractory ...
Patrick DalyOncology | April 22, 2022
Seeking to improve early detection of chronic graft-versus-host disease (cGVHD), Ankit Shah and colleagues tested if ...
Patrick DalyOncology | April 22, 2022
In a poster presented at the Transplantation & Cellular Therapy (TCT) 2022 Tandem Meetings from the American Society ...
Patrick DalyOncology | June 28, 2023
There is a lack of data on cardiac toxicity related to post-transplant cyclophosphamide (PTCY) for graft-versus-host ...
DocWire News EditorsHOPA Annual Conference 2022 | April 12, 2022
Patients receiving haploidentical hematopoietic cell transplantation (haplo-HCT) often develop cytokine release syndrome ...
DocWire News EditorsHOPA Annual Conference 2022 | April 11, 2022
Acute graft-versus-host disease is a leading cause of mortality after allogeneic hematopoietic stem cell transplantation ...
DocWire News EditorsHOPA Annual Conference 2022 | April 8, 2022
Although allogeneic hematopoietic cell transplant (HCT) can cure hematologic disease, the treatment may result in ...
Rebecca AraujoOncology | December 17, 2021
This week on DocWire, we covered the latest breaking research from the American Society of Hematology (ASH) 2021 Annual ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Adoptive immunotherapy with CD4+/CD25/+FOXP3+ regulatory T cells (Tregs) and conventional T cells (Tcons) has been used ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 24, 2023
Updated results from a real-world analysis confirm that ruxolitinib is an effective treatment option for patients with ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | July 5, 2023
The combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 24, 2023
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
Advertisement
Advertisement
Latest News

March 28, 2024